AC Immune interim CEO granted RSUs and options

AC Immune SA interim CEO Martin Zuegel reported equity compensation awards.

Rhea-AI Filing Summary

AC Immune SA interim CEO Martin Zuegel reported equity compensation awards. On June 11, 2026, he received a grant of 33,136 restricted share units under the company’s 2016 Stock Option and Incentive Plan. Following this award, he holds 71,408 common shares underlying outstanding restricted share units.

On the same date, he was also granted share options on 77,778 common shares at an exercise price of $2.6200 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036. All reported holdings are direct.

Insider Trade Summary

Grant/Award: 110,914 shares

Grant/Award 2 txns

Insider Zuegel Martin

Role Interim CEO

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy)	77,778	$0.00	$0.00
Grant/Award	Common Share	33,136	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 77,778 contracts (Direct); Common Share — 71,408 shares (Direct)

Footnotes (3)

1. F1. On June 11, 2026, the Reporting Person received a restricted share unit grant of 33,136 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP).
2. F2. Comprised of 71,408 common shares underlying outstanding restricted share units.
3. F3. On June 11, 2026, the Reporting Person received share options with respect to 77,778 shares under the SOIP. The share options will fully vest on June 10, 2027.

Key Figures

RSU grant: 33,136 units RSU-based shares held: 71,408 shares Option grant size: 77,778 options +3 more

6 metrics

RSU grant 33,136 units Restricted share units granted on June 11, 2026

RSU-based shares held 71,408 shares Common shares underlying outstanding RSUs following grant

Option grant size 77,778 options Share options granted on June 11, 2026

Option exercise price $2.6200 per share Exercise price for 77,778 share options

Option vesting date June 10, 2027 Date options will fully vest

Option expiration June 10, 2036 Expiration date of granted share options

Key Terms

restricted share unit, 2016 Stock Option and Incentive Plan, share options, exercise price, +1 more

5 terms

restricted share unit financial

"received a restricted share unit grant of 33,136 units under the AC Immune SA 2016 Stock Option and Incentive Plan"

A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.

2016 Stock Option and Incentive Plan financial

"grant of 33,136 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP)"

share options financial

"received share options with respect to 77,778 shares under the SOIP"

Share options are contracts that give someone the right, but not the obligation, to buy a company’s stock at a predetermined price for a limited time—think of them like a coupon to purchase shares later at a set price. They matter to investors because when exercised they increase the number of outstanding shares (dilution), can change management incentives and company value, and represent a potential future claim on profits or equity.

exercise price financial

"share options on 77,778 common shares at an exercise price of $2.6200 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The share options will fully vest on June 10, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AC Immune (ACIU) interim CEO Martin Zuegel report in this Form 4?

He reported receiving equity compensation awards, not open-market trades. The filing shows a grant of restricted share units and a grant of stock options under AC Immune’s 2016 Stock Option and Incentive Plan, both awarded on June 11, 2026 as part of his compensation.

How many restricted share units did AC Immune (ACIU) grant to Martin Zuegel?

He received 33,136 restricted share units on June 11, 2026. After this award, his reported position includes 71,408 common shares underlying outstanding restricted share units, reflecting his accumulated RSU-based equity exposure in AC Immune SA as interim CEO.

What stock options did AC Immune (ACIU) grant to Martin Zuegel and at what price?

He was granted options on 77,778 common shares at an exercise price of $2.6200 per share. These options were awarded under the 2016 Stock Option and Incentive Plan and give him the right to buy shares at that fixed price if exercised.

When do Martin Zuegel’s new AC Immune (ACIU) stock options vest and expire?

The options will fully vest on June 10, 2027 and expire on June 10, 2036. Vesting means he must remain eligible until June 2027 to exercise, while the 2036 expiration is the final date the options can be exercised.

Are Martin Zuegel’s AC Immune (ACIU) holdings in this Form 4 direct or indirect?

All reported holdings are direct. The Form 4 lists his ownership type as direct for both the restricted share units underlying 71,408 common shares and the 77,778 stock options, with no indication of trusts or other indirect holding entities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 06:50 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zuegel Martin

(Last) (First) (Middle)

EPFL INNOVATION PARK, BUILDING B

(Street)

LAUSANNE 1015

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
AC Immune SA [ ACIU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Share	06/11/2026		A		33,136	A	$0(1)	71,408(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$2.62	06/11/2026		A		77,778		06/10/2027(3)	06/10/2036	Common Share	77,778	$0	77,778	D

Explanation of Responses:

1. On June 11, 2026, the Reporting Person received a restricted share unit grant of 33,136 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP).

2. Comprised of 71,408 common shares underlying outstanding restricted share units.

3. On June 11, 2026, the Reporting Person received share options with respect to 77,778 shares under the SOIP. The share options will fully vest on June 10, 2027.

	Matthias Maurer as Attorney-in-Fact for Martin Zuegel	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)